Kalaris Share Price

Kalaris Share Price

NASDAQ: KLRS | Micro Cap | Healthcare
$1.25
-$0.11 (-8.09%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Kalaris Stock Performance

Open
$1.33
Prev. Close
$1.36
Circuit Range
N/A
Day Range
$1.32 - $1.36
Year Range
$1.32 - $11.81
Volume
2,530
Average Traded
$1.34

Kalaris Share Price Today

As of 22 November 2026, Kalaris Therapeutics, Inc.'s share price is $1.25. The stock opened at $1.33, compared to its previous close of $1.36. During today's trading session, Kalaris Therapeutics, Inc.'s share price traded between $1.32 and $1.36, with an average price of $1.34. Over the past 52 weeks, the stock has recorded a high of $11.81 and a low of $1.32. In terms of performance, Kalaris Therapeutics, Inc.'s share price has declined by 75.87% over the last six months and is down 79.85% on a year-on-year basis.

Kalaris Share Price Chart

Line chart of the Kalaris price trend over the selected period. The price fell overall, ranging from 1.25 to 1.37, ending at 1.25.
$1.32$1.36
L
Show Current Price
H

Kalaris Stock Fundamentals & Key Indicators

Market Cap
$19.08M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.82
Revenue (TTM)
$0.00
Return On Equity (TTM)
-91.55%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-10.30%

Kalaris Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$10.00-$10.86-$11.52-$11.03
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-8.60%-6.08%4.25%

Kalaris Annual Profit & Loss

All figures in USD

Particulars2025
Revenue$0.00
Net Profit-$43.44
Net Profit MarginN/A
Income ChangeN/A

Kalaris Balance Sheet

All figures in USD Million

Particulars2025
Non Current Assets2.93
Current Assets118.81
Total Assets121.74
Non Current Liabilities33.21
Current Liabilities9.71
Total Liabilities42.92
Shareholders' Equity78.81

Kalaris Cash Flow

Annually

All figures in USD Million

Particulars2025
Operating-38.37
Investing-19.72
Financing155.01

About Kalaris

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Kalaris Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$2.04
$1.36
-32.67%
Oct 2026
$2.80
$2.02
-30.58%
Sep 2026
$3.91
$2.91
-30.30%
Aug 2026
$3.67
$4.17
+17.94%
Jul 2026
$4.43
$3.54
-15.61%
Jun 2026
$5.18
$4.20
-19.02%
May 2026
$5.50
$5.18
-5.99%
Apr 2026
$5.67
$5.51
-5.00%
Mar 2026
$10.45
$5.80
-43.85%
Feb 2026
$9.25
$10.33
+16.46%
Jan 2026
$8.12
$8.87
+5.34%
Dec 2025
$5.95
$8.42
+35.70%

Kalaris Share Price FAQs